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Abstract
Background: Huntington’s disease (HD) is an incurable hereditary neurodegenerative disorder, which manifests
itself as a loss of GABAergic medium spiny (GABA MS) neurons in the striatum and caused by an expansion of the
CAG repeat in exon 1 of the huntingtin gene. There is no cure for HD, existing pharmaceutical can only relieve its
symptoms.
Results: Here, induced pluripotent stem cells were established from patients with low CAG repeat expansion in the
huntingtin gene, and were then efficiently differentiated into GABA MS-like neurons (GMSLNs) under defined culture
conditions. The generated HD GMSLNs recapitulated disease pathology in vitro, as evidenced by mutant huntingtin
protein aggregation, increased number of lysosomes/autophagosomes, nuclear indentations, and enhanced neuronal
death during cell aging. Moreover, store-operated channel (SOC) currents were detected in the differentiated neurons,
and enhanced calcium entry was reproducibly demonstrated in all HD GMSLNs genotypes. Additionally, the
quinazoline derivative, EVP4593, reduced the number of lysosomes/autophagosomes and SOC currents in HD GMSLNs
and exerted neuroprotective effects during cell aging.
Conclusions: Our data is the first to demonstrate the direct link of nuclear morphology and SOC calcium deregulation
to mutant huntingtin protein expression in iPSCs-derived neurons with disease-mimetic hallmarks, providing a valuable
tool for identification of candidate anti-HD drugs. Our experiments demonstrated that EVP4593 may be a promising
anti-HD drug.
Keywords: Huntington’s disease, Human induced pluripotent stem cells, Differentiation, GABAergic medium spiny
neurons, Nuclear indentations, Store-operated calcium entry, Neurodegeneration, Aging, Neuroprotection
Background
Huntington’s disease (HD) is an incurable autosomal dom-
inant hereditary neurodegenerative disorder that typically
manifests between 35–55 years of age. The worldwide
prevalence of HD ranges from 0.5 (Japan) to 5–7 (Europe,
USA, and Canada) cases per 100,000 individuals. HD is
characterized by extensive neurodegeneration, primarily
affecting GABAergic medium spiny (GABA MS) neurons
in the striatum. Other brain regions also show substantial
neuronal damage with disease progression [1].
HD is caused by an expansion of cytosine-adenine-
guanine (CAG) repeats in the huntingtin gene (HTT)
that leads to a pathological elongation of polyglutamine
repeats in the huntingtin protein (HTT). The HD
phenotype develops when the number of trinucleotide
repeats in the HTT gene exceeds 36. The HTT protein
normally interacts with hundreds of other proteins, and
probably has multiple biological functions [2]. While
wild-type HTT (wtHTT) and mutant HTT (mHTT)
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proteins are ubiquitously expressed in the brain, neuro-
degeneration in HD mainly affects the striatum. Further-
more, the neurotoxic actions of mHTT are significantly
higher in the striatal neurons of aged vs. young animals
[3]. Recent magnetic resonance imaging and positron
emission tomography studies demonstrated that striatal
atrophy in human HD patients is detectable even at
10 years before the onset of disease symptoms [4].
Nevertheless, the mechanism of mHTT action is not
fully understood, and is often considered multifactorial.
HD pathology is linked to the deregulation of multiple
cellular processes (e.g., autophagy [5], calcium homeo-
stasis [6], and assorted mitochondrial functions [7, 8]),
but the critical factors behind HD advance are still un-
known. Various challenges complicate the deciphering of
HD molecular mechanisms, including a limited access to
human neurons, the complexity of the molecular mecha-
nisms underlying HD pathology, and the lack of ad-
equate animal models. The discovery of somatic cell
reprogramming technology, as well as the development
of differentiation protocols for human pluripotent stem
cells (PSCs), have jointly engendered new disease models
based on induced PSCs (iPSCs) derived from the som-
atic cells of patients with particular afflictions [9, 10].
Recently, a number of studies have reported that iPSCs
derived from patients with HD (HD iPSCs) are useful
for disease modeling and genetic correction assessment.
In an initial study, HD iPSC-derived neurons with a high
trinucleotide repeat number showed elevated caspase 3/
7 activity during differentiation upon growth factor
deprivation [11]. Interestingly, mHTT aggregates were
detected in undifferentiated HD iPSCs upon proteasome
inhibition or the extended (up to 40 weeks) maintenance
of neural progenitor cells (NPCs) in vivo [12]. Later, HD
iPSCs were used to reverse disease phenotype by a hom-
ologous recombination technique [13]. Nevertheless, HD
iPSC lines carrying homozygous or heterozygous muta-
tions with relatively low repeat numbers (i.e., 39–44) did
not show elevated caspase levels, despite the suggestion
of abnormal protein clearance [14]. Efficient generation
of GABA MS-like neurons (GMSLNs) from ESCs [15]
and HD iPSCs [16] was recently described. HD iPSC
Consortium established and analyzed iPSC lines from
three HD patients carrying various number of repeats
(ranging from 60 up to 180). Similar to transgenic HD
models, the disease phenotype was most pronounced in
neural cell derivatives carrying 180 CAG repeats, al-
though an increased cumulative risk of death was ob-
served for all three HD genotypes (ranging from 60 to
180) relative to wild-type (WT) controls [17].
Despite the progress in iPSC-facilitated HD modeling,
no significant advance in disease prevention or treat-
ment has yet been reported partly because the number
of relevant physiological models is limited. However,
given that faulty calcium signaling reportedly contributes
to disease progression in transgenic animal models,
modified calcium signaling is now regarded as a major
target of medical anti-HD drug development [6].
Here we report the derivation of iPSC lines from the
skin fibroblasts of three human HD subjects carrying low-
CAG repeat numbers (iPSHD11 (Q40), iPSHD22 (Q47),
and iPSHD34 (Q42)), and describe an efficient protocol
for the generation of enriched populations of GMSLNs.
We utilized the established cell model to investigate dis-
ease manifestation and neuroprotective actions of candi-
date pharmacological compounds. Electrophysiology
techniques were employed to measure calcium store-
operated channel (SOC) currents in the differentiated
neurons, and revealed enhanced SOC activity in HD
GMSLNs. A candidate compound effectively decreased
SOC-mediated calcium entry into HD GMSLNs, and pro-
tected aging HD neurons from cell death. Therefore, we
propose that iPSC-differentiated HD GMSLNs, with their
described pathophysiological abnormalities, provide an
appropriate model for both fundamental and applied stud-
ies of neurodegeneration.
Results
Establishment and characterization of human HD iPSC
lines
Cultures of primary dermal fibroblasts were estab-
lished from skin biopsies of three female HD patients.
All three patients gave their written informed consent
for the use of sample material for research purposes.
Fibroblasts from passages 1–3 were used to generate
iPSCs, which were then characterized for pluripotency
marker expression (Additional file 1: Figure S1A). A
normal karyotype was confirmed by GTG-banding
(Additional file 1: Figure S1B).
To validate HD iPSC pluripotency both in vitro
and in vivo, we next investigated the differentiation
capacity of the iPSCs into cells of all three germ
layers and their ability to form teratomas (Additional
file 1: Figure S1C, S1D). One iPSC line from each
patient (namely, iPSHD11, iPSHD22, and iPSHD34)
was selected for further evaluation. The number of
CAG repeats in the selected HD iPSC lines was de-
termined by Sanger sequencing. As a result, the
iPSHD11 line carried 40/17 CAG repeats, while the
iPSHD22 and iPSHD34 lines carried 47/16 and 42/
27 repeats, respectively. Previously described WT
human iPSC lines, endo-iPS12 and IPSRG2L [18],
and one WT human embryonic stem cell (ESC) line,
hESM01 [19], were used as controls. The number of
CAG repeats in the WT lines was determined by RT-
PCR analysis and did not exceed 26–29 (Additional
file 1: Figure S1E).
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Differentiation of human PSCs into GMSLNs
Human PSCs were maintained in mTeSR1 medium and
cultured on a Matrigel™ matrix. A four-step protocol
was developed to differentiate the PSCs into GMSLNs
(Fig. 1a). First, the PSCs were directed toward differenti-
ation into primitive neuroepithelial cells by using
Noggin, SB431542, and dorsomorphin. After 7–9 days of
culture, cell differentiation into primitive neuroepithelial
cells was maintained via use of Noggin, and cell differen-
tiation into lateral ganglionic eminence progenitors was
initiated via use of purmorphamine [15]. This second
differentiation step also required 7–9 days. Next, neural
Fig. 1 Characterization of GMSLNs differentiated from human PSCs. a Schematic representation of differentiation protocol. b Representative image of
NPCs differentiated from hESM01 in phase contrast and immunostained for neuronal markers (SOX2, PAX6, FOXP2, NCAM1, ENO2, and Nestin),
counterstained with DAPI. Scale bar, 50 μm. c Representative image of neurons differentiated from iPSHD34 in phase contrast and immunostained for
DARPP-32, TUBB3, GAT1, and HTT (ab109115), counterstained with DAPI. Scale bar, 50 μm. d Representative RT-PCR analysis of NPCs differentiated from
hESM01 showing expression of genes: GSX2, PAX6, FOXG1, and OTX2. e Representative RT-PCR analysis of neurons differentiated from endo-iPS12 showing
expression of genes: PPP1R1B, GAD1, DRD1, BCL11B, CALB1, SST, RASD2, PENK, ANO3, PDYN, GRIA1, GRIA2, GRIK2, GRIK5, GRIN1, and GRIN2B. f Representative
microphotographs of neurons differentiated from hESM01 acquired via TEM showing dendritic spines and synapse formation. g Cytosolic calcium cation
levels in neurons differentiated from iPSHD22 in response to depolarization of the plasma membrane with potassium chloride (KCl). Cation levels were
monitored by ratiometric Fura-2 imaging. Horizontal lines on the top of the graph indicate the time of application of 2.5 mM Ca2+ or 130 mM KCl into the
culture medium
Nekrasov et al. Molecular Neurodegeneration  (2016) 11:27 Page 3 of 15
rosettes were mechanically replated to separate NPCs
from other cell types, and the NPCs were expanded by
using accutase passaging. NPCs were passaged up to
four times (i.e., up to 50 days), frozen, or used directly
for terminal differentiation.
Characterization of the NPCs using immunocytochem-
ical (ICC) and RT-PCR analyses showed that the cells
expressed SOX2, PAX6, FOXP2, NCAM1, ENO2, Nestin,
GSX2, FOXG1, and OTX2, which are all expressed in de-
veloping striatum [20] (Fig. 1b, d). Following the initial
differentiation procedure, the NPCs were further differ-
entiated with brain-derived neurotrophic factor for
≥10 days for maturation into GMSLNs. ICC demon-
strated that up to 93 ± 5 % of the cells specifically
expressed TUBB3, a neuron-selective marker, while up
to 79 ± 2 % of the TUBB3-positive cells specifically
expressed DARPP-32, a GABA MS neurons marker [21]
(Fig. 1c). The NPC-differentiated neurons also expressed
the synaptic GABA transporter, GAT1, which removes
GABA from the synaptic cleft and is indicative of syn-
apse formation. Almost all of the differentiated HD and
WT GMSLNs were positive for HTT (Fig. 1c).
The nucleus accumbens of the ventral striatum is rep-
resented with almost 95 % of GABA MS neurons there-
fore for additional characterization of the GMSLNs we
accessed transcriptome databases [22, 23] and identified
a group of genes co-expressed in this is region of stri-
atum, but virtually absent from most other brain regions.
GMSLNs differentiated from PSCs expressed all identi-
fied genes, namely PPP1R1B, GAD1, DRD1, BCL11B,
CALB1, SST, RASD2, PENK, ANO3, PDYN (Fig. 1e).
Next, the cultivation medium of the terminally differ-
entiated GMSLNs was withdrawn 30 min after incuba-
tion with cells and subjected to high-performance liquid
chromatography analysis for GABA secretion. Conse-
quently, the average GABA concentration was 508 ±
162 μM. We did not find any reproducible differences
between normal and “diseased” samples. Transmission
electron microscopy (TEM) analysis of differentiated
GMSLNs demonstrated that the neurons had dendritic
spines and were capable of forming synapses (Fig. 1f ).
The functional properties of the differentiated GMSLNs
were then assessed in vitro by their response to
potassium-mediated membrane depolarization. After
depolarization, a significant calcium influx was detected
by Fura-2 imaging (Fig. 1g). Collectively, these data con-
firm that our differentiation protocol generates neuronal
cultures enriched in cell population with morphological
and functional properties of GABA MS neurons.
Recapitulation of disease pathology phenotype in the HD
neuron model
To elucidate specific differences in the ability of patho-
logical vs. normal PSCs to differentiate into neurons, we
examined proliferation rates, NPC forming capacity, and
the relative amount of DARPP-32 positive neurons in
GMSLN cultures generated from the HD and the WT
PSC lines. No significant differences were observed be-
tween the HD and WT cells concerning proliferation
rates, NPC formation, or the proportion of DARPP-32
positive neurons in the last step of differentiation (Add-
itional file 1: Figure S1F, S2A).
We further investigated the in vitro differences be-
tween normal and pathological cultures by confirming
mHTT protein presence in the differentiated HD neu-
rons. Intracellular inclusions of aggregated mHTT are a
hallmark of HD, and are readily demonstrated by using
the EM48 antibody against the accumulated protein
[24]. ICC revealed EM48-positive inclusions in 6-month-
old, mature HD neurons (Fig. 2a), but not in WT neu-
rons (Additional file 1: Figure S2B). Application of the
proteasome inhibitor, MG132, to 6-month-old neurons
at a concentration of 10 μM for 24 h significantly in-
creased the number of EM48-positive inclusions in HD
cultures (Fig. 2a), but not in WT cultures (Additional file
1: Figure S2B).
It was recently reported that aggregated mHTT dis-
rupts the nuclear envelope [25]. Therefore, we investi-
gated the morphology of WT and HD GMSLNs at the
subcellular level via TEM. TEM analysis revealed larger
numbers of lysosomes and autophagosomes, increased
evidence of mitophagy, and a significantly enhanced oc-
currence of nuclear envelope indentations in HD vs. WT
neurons, affecting 85 ± 5 % vs. 58 ± 3 % of the respective
cell population (p < 0.005) (Fig. 2b).
We next performed a flow cytometry (FC) assay on
live LysoTracker Green DND-26-stained GMSLNs to
confirm the increased lysosomal content in HD neurons
(Fig. 2c, Additional file 1: Figure S2C, for details see
Additional file 1). As a result, neurons derived from HD
iPSCs vs. WT PSCs exhibited a significantly higher me-
dian lysosomal content (2203 ± 172 vs. 1539 ± 65 relative
fluorescence units, respectively; p < 0.05) (Fig. 2c).
Nuclear indentations were clearly evident not only by
TEM (Fig. 2b), but also by DAPI staining of HD
GMSLNs (Fig. 2d). To quantitatively assess nuclear in-
dentation events, we conducted a nuclear morphometry
analysis. This method has been successfully used in the
study and diagnosis of various human pathologies [26,
27]. Here, we found a significantly higher mean nuclear
irregularity index in HD neurons (116 ± 3 %, 118 ± 3 %,
and 133 ± 4 % for iPSHD11, iPSHD22, and iPSHD34
lines, respectively; average = 122 ± 3 %) than in WT neu-
rons (95 ± 2 %, 104 ± 3 %, and 101 ± 3 % for endo-iPS12,
IPSRG2L, and hESM01 lines, respectively; average = 100
± 3 %; p < 0.05) (Fig. 2d, g). A comparison of HD and
WT fibroblasts or iPSCs revealed no significant differ-
ences in the nuclear irregularity index, suggesting that
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Fig. 2 (See legend on next page.)
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nuclear envelope impairment was selective for neurons
undergoing further cell damage and death (Additional
file 1: Figure S3A, S3B).
To verify that observed nuclear indentations were
caused by endogenous mHTT we performed an allele-
specific knockdown of mHTT using modified antisense
oligonucleotides LNA(T) and LNA(S) described earlier
[28] to block protein synthesis. It was nearly impossible
to separate by electrophoresis normal and mutant forms
of HTT with just a few amino acids difference, thus for
these experiments we used fibroblasts and neurons from
the cell line with a greatest difference in the number of
repeats iPSHD22 (Q47/16). Transfection of parental fi-
broblasts (data not shown) or iPSHD22 derived neurons
with LNA(T) but not with scrambled LNA(S) resulted in
the significant reduction of mHTT at day 4 (Additional
file 1: Figure S3C). We used transfected neurons to
analyze nuclear indentations. We observed significant
reduction of mean nuclear irregularity index in patho-
logical neurons transfected with LNA(T) compared to
LNA(S) or cells without treatment (p < 0.05) (Fig. 2e).
To prove additionally that mHTT overexpression leads
to the nuclear impairment in any normal neurons we in-
troduced lentiviral constructs containing first exon of
mutant huntigtin (HTTQ138-1exon) or normal hunting-
tin (HTTQ15-1exon) described earlier [29] into WT
PSCs derived neurons. Protein overexpression (Add-
itional file 1: Figure S3D) and nuclear irregularity index
was measured 9 days after infection. We found that nu-
clear irregularity index was significantly higher in cul-
tures of WT neurons infected with HTTQ138-1exon
compared to WT neurons infected with HTTQ15-1exon
constructs (p < 0.05) (Fig. 2f ). These experiments con-
firm that observed nuclear indentations are caused by
the presence of mHTT.
To globally assess the state of the nuclear envelope, we
evaluated HD neurons for the distribution of lamin A,
which provides mechanical strength to the envelope, and
lamin B1, which contributes to envelope integrity [30].
No abnormalities were observed in either gross nuclear
envelope morphology or lamin distribution (Additional
file 1: Figure S3E).
We next investigated the nature of the nuclear indenta-
tions by evaluating the ability of MG132, a proteasomal in-
hibitor, and lithium chloride (LiCl), an autophagy inducer,
to modify nuclear architecture. First, we explored whether
MG132 could enhance the HD phenotype by promoting
mHTT aggregation. Incubation of neurons with MG132
significantly increased the mean nuclear irregularity index
in HD but not WT neurons, with observed post-incubation
values of 123 ± 3 %, 172 ± 4 %, and 155 ± 6 % for iPSHD11,
iPSHD22, and iPSHD34 lines, respectively (average = 150 ±
4 %; p < 0.05 vs. untreated HD neurons) (Fig. 2g, Additional
file 1: Figure S3F). Next we examined the effect of LiCl,
which was suggested recently as a possible drug for the
treatment of HD via its ability to enhance mHTT clearance
[31]. LiCl acted similarly to MG132, and increased the
mean nuclear irregularity index in HD neurons (observed
values = 127 ± 3 %, 126 ± 3 %, and 163 ± 5 % for iPSHD11,
iPSHD22, and iPSHD34 lines, respectively; average = 139 ±
4 %; p < 0.05) (Fig. 2g, Additional file 1: Figure S3F). None-
theless, our findings suppose that even superior mHTT
clearance may be insufficient to protect neurons from nu-
clear indentations. Recently, it was shown that the phos-
phoinositide 3-kinase (PI3K) inhibitor, LY294002, corrected
similar changes in nuclear shape in Parkinson’s disease
(PD) model neurons [26]. Notably, LY294002 significantly
reduced the mean nuclear irregularity index in HD neurons
to 94 ± 2 %, 102 ± 2 %, and 87 ± 3 % for iPSHD11,
iPSHD22, and iPSHD34 lines, respectively (average = 94 ±
2 %; p < 0.005 vs. untreated cells); however, the actions of
the agent were not specific for pathological neurons, be-
cause LY294002-treated WT neurons also showed a signifi-
cant reduction in the nuclear index, with observed post-
incubation values of 82 ± 2 %, 68 ± 8 %, and 71 ± 3 % for
endo-iPS12, IPSRG2L, and hESM01 lines (average = 74 ±
5 %; p < 0.005) (Fig. 2g, Additional file 1: Figure S3F). Al-
though PI3K signaling is involved in nuclear organization,
(See figure on previous page.)
Fig. 2 Phenotypic differences between HD and WT GMSLNs. a Representative microphotographs of 1) neurons differentiated from iPSHD22 cells,
immunostained for microtubule-associated protein 2 (MAP2, red) and HTT (EM48 antibody, green), and counterstained with DAPI (blue); and 2) neurons
differentiated from iPSHD22 cells, immunostained for HTT (EM48 antibody, green), and counterstained with DAPI (blue) following a 24 h incubation with or
without 10 μM MG132. Scale bar, 20 μm. b Representative microphotograph of neurons differentiated from iPSHD22 cells
acquired via TEM. Micrographs show high lysosomal and autophagosomal content, mitophagy, and nuclear envelope indentation. c Representative FC
analysis of live neurons stained with LysoTracker Green; HD (green), WT (blue), and without staining (grey). The bar plot demonstrates median fluorescence
intensity from three independent experiments. d Representative microphotographs of terminally differentiated WT and HD neurons stained with DAPI
demonstrating nuclear indentations. Scale bar, 50 μm. The bar plot demonstrates morphometric quantification of nuclear irregularity index using 786–1340
nuclei per data point. e The bar plot demonstrates morphometric quantification of nuclear irregularity index in cultures of iPSHD22 derived neurons 4 days
after transfection with antisense oligonucleotides: LNA(T) – specifically knockdown mHTT, LNA(S) – scrambled oligonucleotide, Control – no transfection.
754–1405 nuclei were count per data point. f The bar plot demonstrates morphometric quantification of nuclear irregularity index in cultures of WT PSCs
(endo-iPS12, IPSRG2L and hESM01) derived neurons 9 days after infection with lentiviral constructs HTTQ15-1exon and HTTQ138-1exon. 754–1405 nuclei
were count per data point. g Bar plot of the average mean nuclear irregularity index of HD (iPSHD11, iPSHD22, and iPSHD34) and WT (endo-iPS12, IPSRG2L,
and hESM01) neurons after treatment with the indicated drugs. Morphometric quantification was conducted by using 2785–4649 nuclei per data point
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the PI3K cascade is apparently not impaired by mHTT ex-
pression in HD neurons.
Nuclear architecture is important for cellular functions
directly connected with cell specialization and signaling
[32]. Hence, global changes in nuclear structure should be
reflected in gene expression patterns, prompting us to in-
vestigate differences in gene expression between HD and
WT GMSLNs. We performed a comparative microarray-
based transcriptome analysis by using RNA samples iso-
lated from the three HD and three WT lines of differenti-
ated GMSLNs, and identified 183 upregulated and 52
downregulated genes in the HD neurons (Additional file 1:
Table S1). Additionally, we conducted an enrichment ana-
lysis by using the GOrilla web-based application [33] and
demonstrated upregulation of calcium-related pathways in
HD neurons (Additional file 1: Figure S4).
Taken together, the findings presented above demon-
strate that HD iPSC-derived GMSLNs recapitulate mul-
tiple HD phenotypic characteristics and proteasome
inhibition enhances HD manifestation.
Abnormal SOC-mediated calcium entry in human HD
GMSLNs is rescued by EVP4593
The transcriptome data and all abovementioned disease
characteristics (i.e., increased lysosomal/autophagosomal
content and mitophagy, and abnormal nuclear ultra-
structure) are tightly associated with calcium homeosta-
sis, suggesting the possible regulatory role of the latter
in disease control. In this regard, calcium influx through
SOCs is an important and ubiquitous mechanism for
cation entry into mammalian cells, including neurons.
Augmented SOC-mediated calcium entry was previously
demonstrated in transgenic human neuroblastoma cell-
based models of HD [34, 35]. Therefore, we set out to
examine changes in calcium SOC currents between hu-
man HD vs. WT GMSLNs via electrophysiological
means.
To evoke a SOC-mediated calcium entry we used a
standard and ubiquitous protocol with application of 1 μM
Thapsigargin (Tg) [34, 36]. As a result, fully developed Tg-
induced calcium currents exhibited mean amplitudes of
3.93 ± 0.19, 3.74 ± 0.27, and 4.88 ± 0.70 pA/pF in patho-
logical iPSHD11, iPSHD22, and iPSHD34 cell lines, re-
spectively. On the other hand, the Tg-induced currents
exhibited mean amplitudes of only 1.86 ± 0.26, 2.27 ± 0.22,
and 2.07 ± 0.22 pA/pF in WT IPSRG2L, endo-iPS12, and
hESM01 lines, respectively (Fig. 3a, b, e). The average am-
plitudes were 4.10 ± 0.25 pA/pF in HD GMSLNs and 2.07
± 0.22 pA/pF in WT GMSNLNs (Fig. 3f). Thus, the cal-
cium current was ~2-fold higher in neurons derived from
HD iPSCs relative to WT neurons derived from either
iPSCs or ESCs (p < 0.05). Calcium imaging experiments
based on Fura-2 fluorescence confirmed these results, and
showed that SOC-mediated calcium entry was ~3-fold
higher in HD GMSLNs (p < 0.05) (Additional file 1: Figure
S5).
To prove that the observed calcium entry was caused by
mHTT we measured SOC currents in the WT GMSNLNs
infected with described above HTTQ138-1exon and
HTTQ15-1exon lentiviral constructs (Additional file 1: Fig-
ure S3D). We found that the amplitude of SOC currents in
mutant samples (HTTQ138-1exon) was significantly en-
hanced compared to control (HTTQ15-1exon) WT
GMSNLNs, reaching a maximum of 4.22 ± 0.38 and of
1.59 ± 0.20 pA/pF, respectively (Fig. 3c, f). We also found
that allele-specific knockdown of mutant huntingtin ex-
pression in HD GMSLNs using antisense oligonucleotide
(Additional file 1: Figure S3C) decreased amplitude of ab-
normal SOC-mediated calcium entry from 4.62 ± 0.61 pA/
pF in cells transfected with control LNA(S) to 2.29 ± 0.38
pA/pF in cells transfected with LNA(T) targeting mHTT
(Fig. 3d, f). Therefore we could conclude that abnormal
SOC-mediated calcium entry observed in HD human neu-
rons is closely associated with the disease caused by
mHTT.
The ability of the quinazoline derivative, EVP4593, to in-
hibit the SOC-mediated calcium entry pathway in trans-
genic HD animal models was demonstrated [34]. We
therefore evaluated whether EVP4593 could similarly
affect SOC-mediated calcium entry into HD GMSLNs.
Application of EVP4593 at 100 nM to HD and WT
GMSLNs reduced the amplitude of Tg-induced calcium
currents from 4.10 ± 0.25 to 1.49 ± 0.47 pA/pF for HD
neurons (Fig. 4a, c, d), and from 2.05 ± 0.18 to 0.92 ± 0.35
pA/pF for WT neurons (Fig. 4b, d). An analogous effect
was observed with application of 3 μM EVP4593 (data not
shown). These findings demonstrate the latent therapeutic
capacity of EVP4593 to inhibit abnormal SOC currents,
not only in HD neurons of transgenic models, but also in
HD GMSLNs of human patients.
Altogether, the findings described above demonstrate
significant deregulation of calcium transport in human
HD neurons through SOCs within the plasma mem-
brane. Notably, our results also show that HD GMSLNs
respond to pharmacological agents targeted against these
channels. Moreover, it must be emphasized that the cal-
cium currents were recorded from HD GMSLNs ob-
tained from different individuals by different approaches.
The currents still showed similar characteristics, under-
scoring the validity and reproducibility of the iPSC-
based model for HD studies and drug authentication.
EVP4593 normalizes the number of lysosomes/
autophagosomes in HD GMSLNs and rescues aging
neurons from cell death
Normalization of calcium transport within neurons in
response to EVP4593 is expected to reduce pathology
manifestation. Therefore, we evaluated a number of
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lysosomes/autophagosomes in HD and WT neurons
treated with EVP4593 using TEM. We found that incu-
bation with EVP4593 reduced the number of lysosomes/
autophagosomes in HD GMSLNs by almost two-fold
(from 0.41 ± 0.04 to 0.23 ± 0.04; p < 0.05), while WT neu-
rons were not affected (Fig. 5a). This observation was
confirmed by examining lysosome content by FC ana-
lysis. The median fluorescence intensity was reduced
by 34 ± 6 % in HD GMSLNs upon EVP4593 treatment
(p < 0.05) (Fig. 5b). To rule out the possibility that
proinflammatory signaling could be involved in
EVP4593 response we measured NF-κB level in
Fig. 3 (See legend on next page.)
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differentiated neurons. We did not find statistically
significant differences between treated with EVP4593
and untreated samples (Additional file 1: Figure S6).
Because HD has a late onset, neuronal aging might
possibly be involved in the cell death of HD GMSLNs.
The efficiency of the proteostasis network declines with
age, and this failure in protein homeostasis hypothetic-
ally underlies common age-related human disorders
[37]. On these grounds, we established a novel cellular
system by pharmacological means to mimic pathological
neuronal cell death during aging. To do this, we applied
the proteasome inhibitor, MG132, to WT and HD
GMSLNs to model neuronal aging. We then measured
the level of cell death (LoCD) in the neurons, and found
that MG132-treated HD GMSNLNs were more suscep-
tible to cell death (mean LoCD = 195 ± 34 %) than
MG132-treated WT GMSLNs (mean LoCD = 100 ± 9 %;
p < 0.01) (Fig. 5c).
Above, we demonstrated that LY294002 reduced nu-
clear indentations in HD neurons, while EVP4593 nor-
malized SOC-mediated calcium entry and lysosomes/
autophagosomes content. Here, we explored the ability
of EVP4593 and LY294002 to rescue GMSLNs from
MG132-induced cell death. HD and WT GMSLNs were
treated with MG132 and the indicated drug, MG132
alone, drug alone, or solvent alone. The LoCD was mea-
sured in each case, and the differential actions of the in-
dicated drugs against MG132-induced neuronal cell
death (ΔLoCD) were calculated. EVP4593 was the only
drug that significantly and dose-dependently reduced
MG132-induced death of HD GMSLNs, with the highest
efficacy at 100 nM (ΔLoCD = 31 ± 14 %; p < 0.05)
(Fig. 5d).
Discussion
Several PSC lines with mutations in the HTT gene have
been described in earlier work, although the total num-
ber of cell lines carrying any particular number of trinu-
cleotide repeats is still rather limited. Here, we report a
study of HD iPSC lines with a low number of CAG
repeats in the HTT gene that were established from the
skin fibroblasts via lentiviral transduction. As controls,
we included iPSCs established from healthy individuals
[18], and also a previously described human ESC line
[19] to omit possible influences of lentiviral integration.
The obtained pathological and control cells were next
utilized to develop an efficient protocol based on defined
culture medium for their differentiation into GMSLNs.
Up to 80 % of the derived neurons expressed DARPP-
32, a marker widely used for GABA MS neurons [12,
21]. The new protocol described in this paper has the
clear advantage that only well-demarcated chemical
components are employed for cell differentiation. Gener-
ally, our approach is similar to that reported in a previ-
ous study [15], but is adapted to human iPSCs
maintained in mTeSR1 medium, and utilizes lower
amounts of recombinant growth factors and chemical
components.
We compared the cell growth and differentiation
abilities of normal and pathological cell lines, and
failed to observe any differences between the cells.
These findings are consistent with another previously
published report, where HD iPSCs with a low trinu-
cleotide repeat number showed no abnormalities re-
garding proliferation or differentiation capacity [14].
Nevertheless, cells with a higher number of repeats
still readily show a pathological phenotype [17].
Therefore, our investigation of disease pathology in
HD vs. WT cells encompassed two main tasks: first,
to uncover signs of disease manifestation in in vitro-
cultured neurons with a low-CAG repeat number;
and second, to establish a functional in vitro model
reflecting neuronal cell loss during aging.
To accomplish these goals, we took advantage of
TEM to assess the ultrastructure of GMSLNs before
cell death (i.e., prior to evidence of pathology). This
approach revealed multiple differences in neuronal
ultrastructure between WT and HD cells, including
an increased number of autophagosome/lysosome-like
structures in the latter.
(See figure on previous page.)
Fig. 3 Enhanced SOC entry in GMSLNs differentiated from HD iPSCs. a SOC currents amplitudes recorded in whole-cell experiments as a function
of time after application of Tg (1 μM) to HD GMSLNs differentiated from iPSHD11, iPSHD22, and iPSHD34 lines, or WT GMSLNs differentiated from
IPSRG2L, endo-iPS12, and hESM01 lines. Current amplitudes for all groups were measured every 10 s at a test potential of –80 mV. Each plot
shows mean ± SEM. b Average current-voltage (I-V) curves of currents evoked by passive depletion of calcium stores with Tg (1 μM) in GMSNLNs
differentiated from HD iPSCs or WT PSCs. The I-V curves were recorded after full development of the SOC currents. Each trace represents the
average of several experiments. c, d Average current-voltage (I-V) curves of currents evoked by passive depletion of calcium stores with Tg
(1 μM). The I-V curves were recorded after full development of the SOC currents. Each trace represents the average of several experiments. c WT
GMSNLNs infected with mutant HTTQ138-1exon or control HTTQ15-1exon. d In HD GMSNLNs transfected with LNA(T) specifically blocking mHTT
expression or control LNA(S). e Average SOC current amplitude in GMSNLNs differentiated from HD iPSCs or WT PSCs. f Average amplitude of
SOC currents in GMSLNs differentiated from HD iPSCs (black symbols), WT iPSCs (red symbols), WT ESCs (light magenta symbols); in WT GMSNLNs
infected with mutant HTT138Q-1exon (dark green symbols) or control HTT15Q-1exon (orange symbols); in HD GMSNLNs transfected with LNA(T)
(olive symbols) or control LNA(S) (green symbols). e, f For all groups, current amplitude was determined at a test potential of –80 mV and plotted
as the mean ± SEM (n = number of single cell experiments)
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Enhanced lysosomal activity was detected in earlier
studies upon exposure of cells to stress [14]. In our ex-
periments we confirmed this finding in the absence of
cell stress demonstrating 50 % higher lysosomal activity
in HD GMSLNs compared with that in normal controls.
Additionally, our study is the first to identify increased
levels of nuclear indentation in human HD iPSC-derived
GMSLNs. Importantly, nuclear impairment was likewise
demonstrated in earlier work with human postmortem
brain slices of HD patients [38]. Although the molecular
mechanisms particular to this phenomenon still remain
to be investigated, nuclear morphometry clearly indi-
cates a pathological phenotype that could be used to
setup simple and scalable assays to examine the mecha-
nisms involved.
Surprisingly, comparable changes in nuclear shape
were observed in iPSC-derived NPCs carrying a
LRRK2 gene mutation, which results in the develop-
ment of PD [26]. Incorrect protein folding and func-
tion are common in neurodegenerative disorders,
suggesting that similar mechanisms might be involved
in HD and PD pathology. LY294002 was previously
shown to improve nuclear impairments in PD iPSC
NPCs [26], and therefore, we reasoned that its admin-
istration might be helpful for the rescue of HD neu-
rons. Nevertheless, while LY294002 dramatically
reduced the nuclear indentation index in HD neu-
rons, the compound also significantly impacted nu-
clear shape and induced dramatic impairments at the
subcellular level in WT neurons. On the contrary,
LiCl did not alter nuclear architecture in WT neurons
but enhanced indentations in HD neurons. An in-
crease in nuclear irregularity index suggests that other
mechanisms than just impairment of the autophagic
Fig. 4 Reduction of SOC entry activity in HD GMSLNs by EVP4595. a, b Amplitude of Tg (1 μM)-induced currents in whole-cell experiments
performed with (a) HD GMSLNs with (red circles) and without (black squares) EVP4593 (100 nM), or (b) WT GMSLNs with (red circles) and without (black
squares) EVP4593 (100 nM). The 0 s data point corresponds to the time of Tg application. SOC amplitudes were measured at each ramp at a test potential
of –80 mV. The time of EVP4593 application is shown above the plots. Each plot shows the results of one representative experiment. c Average I-V
relationships for currents evoked by passive depletion of calcium stores with Tg (1 μM) in (1) HD GMSLNs after the currents reached the maximum (black
line) and again after application of EVP4593 (100 nM) (red line), or (2) WT GMSLNs after the currents reached the maximum (blue line). Each trace represents
the average of several experiments. d Average amplitude of SOCs in HD GMSLNs with (red) and without (black) EVP4593 (100 nM), or WT GMSLNs with
(teal) and without (blue) EVP4593 (100 nM). The current amplitude for all groups was determined at a test potential of –80 mV and plotted as the mean ±
SEM (n = number of single cell experiments)
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clearance of the excessive mHTT were responsible for
nuclear envelope indentations in HD neurons.
We further investigated disease manifestation at the
molecular level via transcriptome analysis, and found
that nearly 200 genes changed their expression in HD
vs. WT GMSLNs. Most of the identified genes are
purportedly involved in calcium ion binding and cal-
cium signaling, consistent with other findings of gene
expression in HD neural cells [17, 39]. Moreover, we
observed changes in the expression levels of tran-
scripts identified in previous studies as contributing
to pathology manifestation or mutant protein process-
ing. For example, HD neurons showed an upregula-
tion of IFT57, which could possibly trigger caspase-8
activation and neuronal death [40], as well as ARH-
GEF6, which enhances mHTT aggregation [41], and
IRS2, which is required for mHTT clearance [42].
Surprisingly, our HD GMSLN cultures also overex-
pressed transcripts (i.e., TIMP1 and IER3 mRNAs, see
Additional file 1: Table S1) that were recently pro-
posed as HD biomarkers [43, 44].
We specifically aimed to disclose possible alterations
in calcium homeostasis in our newly developed HD iPSC
model. The role of calcium in HD pathogenesis has been
extensively studied over the past decade [45]. Addition-
ally, neuroblastoma cells expressing mHTT with 138
glutamine residues exhibit heightened SOC-mediated
calcium entry pathway activity, and the small-molecule
compound, EVP4593, which was initially found in a
Drosophila screen, can successfully normalize SOC-
mediated calcium entry [34].
It is generally accepted that transgenic HD models
with low trinucleotide repeat numbers are not suitable
for disease studies due to the lack of a functional pheno-
type. Meanwhile, HD manifestation is observed in
humans with CAG repeat numbers reaching 36 and
more. Therefore, we utilized iPSCs with different num-
bers of CAG repeats to optimize our results, and
Fig. 5 Protection of aging HD GMSNLNs from premature cell death. a The number of autophagosomes/lysosomes per μm2 in WT (hESM01) and HD
(iPSHD22) GMSLNs after EVP4593 (1 μM) treatment for 14 h. The number of sections counted was 7-32 per bar. b Representative FC analysis of iPSHD22
MSNs stained with LysoTracker Green without treatment (green) and after 24 h incubation with EVP4593 100 nM (blue). c LoCD of WT and HD GMSLNs
upon MG132-induced cell aging using 24 h 10 μM MG132 treatment. The WT value represents the mean LoCD for endo-iPS12-, IPSRG2L-, and
hESM01-derived neurons, while the HD value represents the mean LoCD for iPSHD11-, iPSHD22-, and iPSHD34-derived neurons (n = 30). d EVP4593
safeguards against MG132-induced cell death in a dose-dependent manner. The WT value represents the mean ΔLoCD for endo-iPS12-, IPSRG2L-, and
hESM01-derived neurons and the indicated drug, while the HD value represents the mean ΔLoCD for iPSHD11-, iPSHD22-, and iPSHD34-derived
neurons and the indicated drug (n = 12). Each error bar represents the SEM
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recorded SOC currents in GMSLNs differentiated inde-
pendently from various HD and WT cell lines. Subse-
quently, HD neurons carrying 40–47 glutamine residues
reproducibly exhibited 2-fold higher SOC currents rela-
tive to WT neurons harboring less than 29 repeats, and
the elevated SOCs activity was accompanied by lyso-
somal accumulation in HD neurons. This is important
because lysosomes share calcium storage functions with
the endoplasmic reticulum, and lysosomal calcium can
be released via transient receptor potential family chan-
nels [46]. Importantly, we failed to observe any differ-
ences between neurons differentiated from iPSCs or
ESCs at the level of our present analyses, thus support-
ing the hypothesis that cell reprogramming introduces
no significant epigenetic changes into final cell charac-
teristics. Furthermore, the previously described
quinazoline-derived compound, EVP4593, normalized
calcium homeostasis and SOC currents in all patient-
specific samples of pathological neurons, demonstrating
its potential therapeutic utility. Additionally, we found
that EVP4593 normalized lysosomes/autophagosomes
content in HD GMSLNs indicating that the abnormal-
ities in these systems are possibly mediated by Ca2+ dys-
homeostasis rather than by autophagy impairment.
We next assessed the capacity of EVP4593 to defend
aged HD neurons against MG132-induced neurotoxicity.
HD has a late onset, and accordingly, neuronal cell loss
is not generally observed in established HD models dur-
ing their typically short time in culture (2–4 months).
The proteasome is a major proteolytic system in mam-
malian cells, and carries out normal protein degradation
as well as degradation of abnormal proteins that tend to
accumulate during aging. Impairment of proteasome
function is therefore tightly correlated with aging both
in vivo and in vitro. In our model system, MG132-
mediated proteasome inhibition enhanced the HD
phenotype at the subcellular level, leading to increased
formation of mHTT aggregates and nuclear indenta-
tions, and ultimately exacerbating neuronal cell death.
However, EVP4593 significantly mitigated the MG132-
induced cell death of HD GMSLNs.
Our findings together with the previously reported
neuroprotective effects of EVP4593 in glutamate-toxicity
assays [34], and the fact that EVP4593 acts at nanomolar
concentrations, introduce this small molecule as a valu-
able new candidate for anti-HD drug development.
Conclusions
In summary, we established an iPSC-derived cellular
model of HD that showed disease manifestation in ma-
ture and aged neurons. We used three different patient-
specific iPSC-derived cell lines to carefully evaluate the
hypothesis that disrupted calcium signaling is behind
HD pathology. Our results clearly support previous
findings of calcium deregulation in HD, and suggest that
this phenomenon may also underlie other HD symp-
toms. We also demonstrated enhanced SOCs activity in
HD GMSLNs, and the promising neuroprotective prop-
erties of EVP4593 to reverse this process. Therefore, the
iPSC model instituted herein may provide a useful plat-
form for future fundamental studies of HD and drug
development.
Methods
Cultivation of human PSCs and generation of iPSCs
iPSCs were generated as described in Additional file 1.
The PSCs were cultured in mTeSR1 medium (Stemcell
Technologies, Canada) on a Matrigel™ substrate (BD
Biosciences, USA). Cells were passaged by using 1 mg/
ml dispase neutral protease (Invitrogen, USA) and cryo-
preserved in mFreSR1 medium (Stemcell Technologies).
Neuronal differentiation of human PSCs
Human PSCs were cultured in mTeSR1 medium on
Matrigel™ until they reached 80–90 % confluency. The
culture medium was then replaced with a 1:4 mixture of
mTeSR1 and K-1 medium (see Additional file 1) for
2 days. The cells were maintained in K-1 medium for 5–
7 days and in K-2 medium for the next 7–9 days. Next,
the cells were transferred to K-3 medium, and neural ro-
settes were replated mechanically. NPCs were expanded
by replating the cells with StemPro Accutase Cell Dis-
sociation Reagent (Life Technologies, USA), followed by
maintenance on Matrigel™ in K-3 medium until passage
4. At this time, the NPCs were transferred to K-4
medium for ≥10 days to generate mature neurons.
To prepare GMSLNs for electrophysiological record-
ing and Fura-2 calcium imaging, differentiated neurons
were plated onto 3 mm coverslips for 7–14 days prior to
analysis. Twenty-four hours before analysis, the K-4
medium was exchanged with Neurobasal A Medium
(Life Technologies) containing 3 % fetal bovine serum
and 3 % B27 supplement (Life Technologies).
Electrophysiological studies
Calcium currents were registered by using a whole-cell
patch-clamp technique [47]. The measurements were
taken with an Axopatch 200B Amplifier (Axon Instru-
ments, USA). Microelectrode resistance was equivalent
to 5–10 MOm; the series resistance was not compen-
sated. Series resistance values were in range of 10–25
MOm and controlled all along the experiment. The cur-
rents were sampled at 5 kHz and filtered digitally at
500 Hz. pClamp6 software (Axon Instruments) was used
for data acquisition and analysis. In all experiments, the
holding potential was –40 mV. Membrane potential was
periodically (every 5 s) dropped to –100 mV (for 30 ms),
then gradually (1 mV/ms) increased to +100 mV and
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then returned to –40 mV. Measurements were made at
0.5-mV intervals. Registered currents were normalized
to cellular capacitance (10–30 pF). The traces recorded
before current activation were used as templates for leak
subtraction. The pipette solution contained (in mM) 125
CsCl, 10 EGTA-Cs, 30 HEPES-Cs, 4.5 CaCl2, 1.5 MgCl2,
4 Na-ATP, pH 7.3. The extracellular solution contained
(in mM) 140 NMDG-Asp, 10 BaCl2, 30 HEPES-Cs, 0.01
nifedipine, and 0.001 tetrodotoxin, pH 7.3. Currents
were evoked by application of 1 μM Tg to the external
solution.
Quantitative analysis of cell nuclear morphology
Neurons were cultured in a 48-well plate in K-4 medium
and treated with the indicated chemical compounds for
24 h before fixation. Cells were then fixed with 4 % para-
formaldehyde (Sigma-Aldrich, USA) for 20 min at room
temperature and stained with DAPI (Sigma-Aldrich).
Images of 6–12 random fields in each well were ob-
tained in a blind fashion using an Axiovert 40 CFL
Fluorescence Microscope (Zeiss AG, Germany). The nu-
clear irregularity index was calculated using automatic
processing of the images by the computer program. To
identify cell nuclei the same hyperparameters were used
for the whole experiment. The following equation was
employed to calculate nuclear irregularity index: (nuclear
perimeter2)/(4 × π × area). The nuclear irregularity index
of WT neurons was taken to be 100 %. Calculations
were performed with self-developed software, available
on demand.
Allele-specific mHTT knockdown using antisense
oligonucleotides
Antisense oligonucleotides LNA(T) and LNA(S) de-
scribed earlier [28] have the following sequences
gcTgcTgcTgcTgcTgcTg and gcTatAccAgcGtcGtcAt, re-
spectively. Locked nucleic acids are shown in capital.
LNAs were synthesized and purified by DNA Synthesis
LTD (Russia). Cells were plated on 48-well dishes at
100,000 cells/well. Stock solutions of oligonucleotides
were heated at 65 °C for 5 min prior to use to dissolve
any aggregates. Cells were transfected using TransIT®-
LT1 Transfection Reagent (Mirus Bio, USA) according
to the manufacturer’s instructions (1.5 μL of lipid
was used for 100 pmol of oligos). mHTT knockdown
was accessed by Western blotting four days after
transfection.
Quantitative analysis of cell death
Cells were cultured in K-4 medium in a 96-well black
plates with clear flat bottom (Corning, USA). Next, cells
were treated with chemical compounds for 24 h prior to
analysis. Fluorescent assay MultiTox-Fluor Multiplex
Cytotoxicity Assay (Promega, USA) was used to measure
simultaneously the relative number of live (viability) and
dead (cytotoxicity) cells in each well according to the
manufacturer’s instructions. Fluorescence was detected
by DTX 880 Multimode Microplate Reader (Beckman
Coulter, USA). To evaluate the level of cell death
(LoCD), the following equation was employed: ([cytotox-
icity in a well with cells] − [cytotoxicity in a well without
cells])/([viability in a well with cells] − [viability in a well
without cells]). The LoCD of MG132-treated WT neu-
rons was regarded as 100 %. To screen putative thera-
peutic compounds in the MG132-induced cell aging
model, the following equation was used to determine
differential action of the drug against MG132-induced
neuronal cell death (ΔLoCD): ([LoCD in a well with
10 μM MG132 and drug] − [LoCD in a well with drug
alone] − [LoCD in a well with 10 μM MG132 alone]
+ [LoCD in a well without MG132 or drug]).
Microarray gene expression data
The microarray data was generated using HumanHT-12
v4 Expression BeadChip (Illumina, USA) according to
manufacturer instructions and deposited in the Gene Ex-
pression Omnibus (GEO) database (accession number
GSE77558). For details see Additional file 1.
Statistical analysis
Each experiment was repeated at least three times.
Quantifiable data are given as the mean ± the standard
error of the mean. Comparisons of means were per-
formed by using a one-tailed Student’s t-test or a one-
tailed Welch’s t-test for unequal variances. In all cases,
p-values <0.05 indicated statistically significant differ-
ences between means.
Additional file
Additional file 1: Figure S1. PSC lines characterization. Figure S2.
HD and WT PSC derived neurons analysis. Figure S3. Nuclear
indentations in HD PSC derived neurons. Figure S4. Classification
of up-regulated genes in HD neurons compared to WT neurons
with GOrilla tool by molecular function. Figure S5. Calcium entry
evoked by store depletion is significantly increased in HD iPSCs
derived neurons. Figure S6. NF-κB activity in PSCs derived neurons.
Table S1. Differentially expressed genes in HD iPSCs derived
neurons. (DOC 8958 kb)
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